IRAK4-IN-20
IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research[1].
Product Specifications
CAS Number
1931994-80-7
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
IRAK
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/irak4-in-20.html
Purity
97.04
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=NC(C(F)(F)F)=CC=C1)NC2=CC3=CN(CCC(C)(O)C)N=C3C=C2C(C)(O)C
Molecular Formula
C22H25F3N4O3
Molecular Weight
450.45
Precautions
H315, H319, H335
References & Citations
[1]Li Q, et al. Oral IRAK4 Inhibitor BAY-1834845 Prevents Acute Respiratory Distress Syndrome. Biomedicine & Pharmacotherapy, 2022: 113459.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IRAK4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/3055), CF405S conjugate, 0.1mg/mL
